MSI and human epidermal growth factor receptor 2 (HER2) amplification are reported to be mutually exclusive, suggesting that HER2 amplification could be a negative predictive marker for immunotherapy in GC patients [97]. The gene discussed is ERBB2; the disease is gastric cancer.